LAVA Therapeutics NV

Company Profile

LAVA Therapeutics NV had its IPO on 2021-03-25 under the ticker symbol LVTX.

The company operates in the Healthcare sector and Biotechnology industry. LAVA Therapeutics NV has a staff strength of 69 employees.

Stock update

Shares of LAVA Therapeutics NV opened at $1.72 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $1.66 - $1.72, and closed at $1.72.

This is a +1.18% increase from the previous day's closing price.

A total volume of 6,880 shares were traded at the close of the day’s session.

In the last one week, shares of LAVA Therapeutics NV have slipped by -3.37%.

LAVA Therapeutics NV's Key Ratios

LAVA Therapeutics NV has a market cap of $46.27 million, indicating a price to book ratio of 1.8811 and a price to sales ratio of 5.8096.

In the last 12-months LAVA Therapeutics NV’s revenue was $24.26 million with a gross profit of $-20714000 and an EBITDA of $-39559000. The EBITDA ratio measures LAVA Therapeutics NV's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, LAVA Therapeutics NV’s operating margin was -165.41% while its return on assets stood at -21.09% with a return of equity of -51.44%.

In Q2, LAVA Therapeutics NV’s quarterly earnings growth was a positive 0% while revenue growth was a positive 998.1%.

LAVA Therapeutics NV’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-1.5 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into LAVA Therapeutics NV’s profitability.

LAVA Therapeutics NV stock is trading at a EV to sales ratio of 4.9353 and a EV to EBITDA ratio of -2.6193. Its price to sales ratio in the trailing 12-months stood at 5.8096.

LAVA Therapeutics NV stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$122.54 million

Total Liabilities

$22.33 million

Operating Cash Flow

$0

Capital Expenditure

$224000

Dividend Payout Ratio

0%

LAVA Therapeutics NV ended 2024 with $122.54 million in total assets and $0 in total liabilities. Its intangible assets were valued at $122.54 million while shareholder equity stood at $63.89 million.

LAVA Therapeutics NV ended 2024 with $0 in deferred long-term liabilities, $22.33 million in other current liabilities, 3715000.00 in common stock, $-134709000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $87.61 million and cash and short-term investments were $112.40 million. The company’s total short-term debt was $5,636,000 while long-term debt stood at $0.

LAVA Therapeutics NV’s total current assets stands at $118.52 million while long-term investments were $0 and short-term investments were $24.80 million. Its net receivables were $4.38 million compared to accounts payable of $5.07 million and inventory worth $0.

In 2024, LAVA Therapeutics NV's operating cash flow was $0 while its capital expenditure stood at $224000.

Comparatively, LAVA Therapeutics NV paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$1.72

52-Week High

$7.38

52-Week Low

$1.365

Analyst Target Price

$6.6

LAVA Therapeutics NV stock is currently trading at $1.72 per share. It touched a 52-week high of $7.38 and a 52-week low of $7.38. Analysts tracking the stock have a 12-month average target price of $6.6.

Its 50-day moving average was $1.84 and 200-day moving average was $2.54 The short ratio stood at 0.86 indicating a short percent outstanding of 0%.

Around 2858.1% of the company’s stock are held by insiders while 4226.9% are held by institutions.